Shamburg News · 8-K filed Nov 16, 2026, 6:08 AM EST
Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab BLA in Lung Cancer
SMMT · Summit Therapeutics Inc.
- Other event
- Material agreement
- Materiality: high
On November 15, 2026, Summit Therapeutics Inc. announced that the FDA issued a Complete Response Letter for the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for previously EGFR TKI-treated locally advanced or metastatic non-small cell lung cancer. The FDA stated the BLA cannot be approved in its present form because substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that the progression-free survival benefit alone does not support approval. The company disclosed the CRL in a press release attached as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001599298-26-000092.
Written from the filing by Shamburg Markets. Figures are as reported by the company.